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1. Introduction 
Cyclophosphamide (CP), an antineoplastic and 
immunosuppressive drug has been widely used in the 
acute treatment of various neoplastic diseases. 
Cyclophosphamide is well known to cause various 
histopathologic patterns of lung injury (Kim et al., 2012). 
Early histologic findings usually demonstrate endothelial 
damage, granular pneumocyte injury, pulmonary edema, 
hemorrhage and cellular inflammatory infiltration 
(Kanekal et al., 1992; Venkatesan and Chandrakasan, 
1995). Although the mechanism(s) of CP-mediated lung 
injury is incompletely understood, generation of reactive  
oxygen species and lipid peroxidation in lung 
microsomes are thought to be involved. Several classes 
of antioxidant dietary compounds have been suggested 
to have health benefits. The evidence shows that the 
consumption of these products leads to decreases in 
various proinflammatory and/or oxidative stress 
biomarkers (Vouldoukis et al., 2004). Quercetin (Qur), is 
a flavonoid, which is present in fruits, vegetables, and 
several other dietary sources (Pawlikowska-Pawlega et 
al., 2003). It is marketed as a diet supplement with 
antihistaminic, anti-inflammatory, antiviral, 
immunomodulatory, and antioxidant properties (Ross 
and Kasum, 2002). In the present study, we aimed to 
Quercetin (Qur), a polyphenolic flavonoid compound present in large 
amounts in vegetables and fruits, plays important roles in human health 
through its antioxidant activity. This study was conducted to investigate the 
possible modulatory effect of Qur against cyclophosphamide (CP)-induced 
lung oxidative damage and to highlight the underlying mechanisms of such 
effect. Male Sprague-Dawely rats were divided into four groups. Group I was 
control. Group II received Qur (100 mg/kg/d. p.o.) for 14 consecutive days. 
Group III was injected once with CP (150 mg/kg, i.p.). Group IV received Qur 
for 7 consecutive days, before and after CP injection.  
 
A single i.p. injection of CP markedly increased the level of serum biomarkers; 
total protein, LDH. Cyclophosphamide significantly increased the lung 
content of lipid peroxides and decreased levels of reduced glutathione. 
Treatment of rats with Qur for 7 days prior to and 7 days after 
cyclophosphamide significantly ameliorated the alterations in lung and serum 
biomarkers associated with inflammatory reactions. Moreover, Qur 
attenuated the secretion of pro-inflammatory cytokine, TNF-α in rat serum. In 
addition, Qur slightly ameliorated CP-induced histopathological changes in 
lung tissue. 
 
Our results suggest that Qur produces a protective effect against CP-induced 
lung injury and suggest a role of oxidative stress and inflammation in the 
pathogenesis.  
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investigate the possible protective effect of quercetin on 
the antioxidative system and inflammatory cytokines in 
the lung after CP therapy. 
 
 
2. Materials and methods 
2.1. Animals 
Male Sprague Dawley rats weighing 170-280 g were 
used in all of the experiments. They were obtained from 
Urology and Nephrology Center of Mansoura University, 
Mansoura, Egypt. The animals were maintained under 
standard conditions of temperature 24 ± 1oC and 55 ± 5% 
relative humidity with regular 12 h light/12 h dark cycles. 
They were allowed free access to standard laboratory 
food and water. The experiments were conducted in 
accordance with the ethical guidelines for investigations 
in laboratory animals and were approved by the Ethical 
Committee of Faculty of Pharmacy, Mansoura University, 
Egypt in accordance with “Principles of Laboratory 
Animal Care” (NIH publication No.85-23, revised 1985). 
 
2.2. Drugs and Chemicals 
 Cyclophosphamide was obtained  as  
pharmaceutical drug  (Endoxan vial 200 mg). Quercetin 
was obtained from (Sigma Chemical Company St. Louis, 
MO, USA). All other chemicals used in this study were of 
fine analytical grade. 
 
2.3. Experimental protocol 
The animals were divided at random into four 
groups of 8 rats each. The first group (control) received 
vehicle used for Qur (CMC). The second group, received 
Qur (100 mg/kg/d. p.o.)for 14 consecutive days. The third 
group was injected once with CP (150 mg/kg, i.p.). The 
fourth group received Qur for 7 consecutive days, before 
and after CP injection. In this group, CP (150 mg/kg, i.p.) 
was injected once on day 7, 1 h after Qur 
administration.On the seventh day following CP 
injection, blood samples were taken under light ether 
anesthesia. Serum was separated by centrifugation for 5 
min at 4000 rpm and stored at −20oC until TNF-α assay. 
Fresh serum was used to estimate total protein level and 
LDH activity.All rats were weighed and then killed by an 
overdose of ether. The lungs were isolated, washed with 
chilled 1.15% KCl (pH 7.4). The left lungs were used for 
determination of thiobarbituric acid-reactive substances 
(TBARS) levels, reduced glutathione contents (GSH) and 
superoxide dismutase activities (SOD). The right lungs 
were fixed in 10% neutral buffered formalin for 
histopathological examinations. 
 
2.4. Biochemical Estimation 
2.4.1. Estimation of serum total protein and LDH 
These estimations were done according to the 
standard procedures given along with the kits 
purchased. Kits from BioMed-Diagnostics, Egy-Chem Co., 
Egypt were used.Estimation of serum total 
proteindepends on thereaction of protein with copper 
ions (ii) to produce a blue violet color compound in 
alkaline medium. The color intensity is proportional to 
the concentration of total protein present in the sample. 
Detection of serum LDH depends on the conversion of 
pyruvate to lactate by LDH consuming NADH+, which 
absorbs light at 340 nm. Its consumption is directly 
proportional to serum LDH concentration. LDH activity 
was calculated as units per litre. 
 
2.4.2. ELISA detection of serumTNF-α level 
 Enzyme-linked immunosorbent assays (ELISAs) 
were used to detect TNF-α level in rat serum according 
to the manufacturer’s manual (Quantikine R&D system 
Inc, Minneapolis, MN). All TNF-α determinations were 
performed in duplicate serial dilutions. Absorbance was 
read on a microplate reader and the concentrations 
were calculated from the standard curve. 
 
2.4.3. Preparation of lung homogenate 
             The isolated left lungs were rinsed in chilled 1.15% 
KCl (pH 7.4) and weighed quickly. Subsequently, the 
lung/body weight ratio was determined. 
Homogenization was carried out in ice-cold KCl (1.15%, pH 
7.4) to yield 10% w/v tissue homogenates (Daba et al., 
2002) and the following biochemical parameters were 
assessed.  
 
2.4.4. Determination of Lipid peroxidation (LP) 
 The level of LP in the lung was estimated as 
TBARS according to Ohkawa et al. (1979). The 
absorbance was determined at 532 nm spectrophoto-
metrically and the concentrations were expressed as 
nmol/g wet tissue.  
 
2.4.5. Determination of reduced glutathione (GSH) 
            The level of acid-soluble thiols, mainly GSH, in the 
lung was assayed colourmetrically, based on its reaction 
with Ellman’s reagent according to the method earlier 
described by Ellman (1959). The absorbance was 
measured at 412 nm and the concentrations were 
expressed mol/g wet tissue. 
 
2.4.6. Determination of superoxide dismutase (SOD) 
 The enzymatic activity of SOD was assessed 
according to Marklund (1985). SOD activity was 
expressed as U/g wet tissue. One unit of SOD activity is 
defined as the amount of the enzyme causing 50% 
inhibition of auto-oxidation of pyrogallol. 
 
2.5. Histopathological analysis 
 The right lungs were rapidly removed from the 
animal, sliced transversely, paraffin embedded, and 
prepared as 3µm thickness sections stained with 
hematoxylin and eosin (H&E) for light microscopic 
evaluation. Histopathological examination of the lung 
sections was performed without knowledge of the 
treatment protocol, as described previously.  
 
2.6. Statistical analysis  
            Data are expressed as mean ± S.E.M. (Significance 
was calculated at p<0.05). Statistical analysis was carried 
out using one way analysis of variance (ANOVA) 
followed by Tukey-Kramer multiple comparisons test 
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(Daniel, 1991). Also paired Student’s t-test was used as a 
test of significance for comparison between two 
arithmetic means of the same subject before and after 
treatment (Daniel, 1991). Statistical calculations were 
carried out using Instat-2 computer program (GraphPad 
Software Inc. V2.04, San Diego, CA, USA).  
 
3. Results 
3.1. Effect of CP and/or Qur on body weight and 
lung/body weight ratio  
The average body weight of normal control animals 
increased significantly after 14 days (20.6% increase). 
Administration of CP alone induced a significant 
decrease in the average body weight (9.5% reduction). 
Qur-treated group showed a similar increase as in the 
control group. Animals treated with CP and Qur showed 
a significant decrease in their body weight by 7.4% which 
is non-significantly different from CP-treated animals 
(Table 1).  
CP administration induced a significant increase in 
lung/body weight ratio of the rats compared to control 
non–treated animals. Combination of Qur with CP 
showed a significant decrease in lung/body weight ratio 
of the rats when compared to CP treated group (Table 
1).
 
Table 1.Effect of cyclophosphamide (CP,150 mg/kg) and/or quercetin (Qur, 100 mg/kg) on body weight and lung/body weight ratio 
of rats  
 
Data are expressed as mean ± SEM, n=8.  
° significantly different from its corresponding initial value using paired Student's t-test (p<0.05). 
* significantly different from control group using One-Way ANOVA followed by Tukey-Kramer multiple comparisons test (p<0.05). 
# significantly different from CP-treated group using One-Way ANOVA followed by Tukey-Kramer multiple comparisons test (p<0.05). 
 
 
3.2. Effect of CP and/or Qur on serum total protein, 
LDH and TNF-α 
Administration of CP alone induced a significant  
increase in serum total protein and LDH activity by 61.4% 
and 126.6%, respectively compared to control non-
treated group (Table 2). Qur-treated group showed non-
significant change compared to control non–treated 
group. Animals treated with CP and Qur showed a 
significant decrease in serum total protein and LDH by 
14.5% and 28.4%, respectively, compared to CP treated 
group (Table 2). 
 
Table 2. Effect of cyclophosphamide (CP,150 mg/kg) and/or 
quercetin (Qur, 100 mg/kg)  on serum total protein 
and LDH  
Treatment 
Total protein 
(g/dl) 
LDH 
(U/L) 
Control 4.898 ± 0.111 123.7  4.8 
CP 7.903 ± 0.242* 280.3  16.3 * 
Qur 5.144  0.183# 115.8  8.3# 
CP/Qur 6.75  0.29*# 200.7  4.9*# 
 
Data are expressed as mean ± SEM, n=8. 
*significantly different from control group using One-Way 
ANOVA followed by Tukey-Kramer multiple comparisons test 
(p<0.05). 
#significantly different from CP-treated group using One-Way 
ANOVA followed by Tukey-Kramer multiple comparisons test 
(p<0.05). 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.  Effect of cyclophosphamide (CP,150 mg/kg) and/or 
quercetin (Qur, 100 mg/kg)  on serum  TNF-α. 
* significantly different from the corresponding mean value of 
control group (p<0.05). 
# significantly different from the corresponding mean value of 
CP-treated group (p<0.05). 
Statistical comparisons were performed usingOne-Way ANOVA 
followed by Tukey-Kramer multiple comparisons test (p<0.05). 
 
 
Treatment 
Body weight (g) Lung/body  
weight ratio  
(  10-3 ) Before treatment After treatment 
% Change in body 
weight 
Control 179.9  6.241 217.5 6.439º 20.9 ↑ 6.4  0.2 
CP 182.1  5.111 164.9  5.097° 9.46 ↓ 7.9  0.3* 
Qur 177.8  6.62 210.6  5.754° 18.4 ↑ 6.8  0.3# 
CP/Qur 273.3  11.81 253.0  13.13° 7.4 ↓ 5.4  0.3# 
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CP-treated group produced an increase in the level of 
serum TNF-α  by 226.3% compared to control non-treated 
group. Animals treated with CP and Qur showed a 
significant decrease in the levels of serum TNF-α 
compared to CP treated  group animals (Figure 1). 
 
3.3. Effect of CP and/or Quron lung content of TBARS, 
GSH and SOD  
 
CP induced a significant increase in lung TBARS 
level compared to control non-treated rats by 90%. 
Administration of Qur for 7 days prior to and 7 days after 
CP showed significant decrease in the level of TBARS 
compared to CP alone by about 29% (Table 3).  
CP induced a significant decrease in lung GSH level 
compared to control non-treated group (83% decrease). 
Administration of Qur for 7 days prior to and after CP 
produced a significant increase in lung GSH level 
compared to CP group (Table 3).  
CP-treated group showed a significant increase in 
lung SOD activity by 95.5%, when compared to control 
non-treated group. Administration of Qur with CP 
showed a significant decrease in lung SOD activity when 
compared to CP group (Table 3). 
 
Table 3. Effect of cyclophosphamide (CP, 150 mg/kg) and/or quercetin (Qur, 100 mg/kg) on lung antioxidant status 
 
Treatment 
TBARS 
(nmol/g wet tissue) 
GSH 
(μmol/g wet tissue) 
SOD 
(units/g wet tissue 
Control 63.63 2.322 0.667.0298 27.51.24 
CP 121.4 7.154* 0.112 0.0093* 53.75 0.701* 
Qur 60.38 5.003# 0.5190.0295# 28.500.98# 
CP/Qur 86.0 6.251# 0.201 0.021*# 32.50 2.32# 
 
Data are expressed as mean ± SEM, n=8. 
* significantly different from control group using One-Way ANOVA followed by Tukey-Kramer multiple comparisons test (p<0.05). 
# significantly different from CP-treated group using One-Way ANOVA followed by Tukey-Kramer multiple comparisons test (p<0.05). 
 
 
3.4. Effect of combination of Qur with CP on 
histopathological analysis in CP-treated rats 
 
Control rats showed no abnormality for the lung 
histology as well as those treated with Qur alone. In CP-
treated animals, histopathological study revealed foci of  
 
oedema and congestion, alveolar septa thickening by 
macrophages and lymphocytes and the alveolar lining is 
prominent. Photomicrographs of representative 
histological sections of the lung can be seen in figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig2. Light microscopy photomicrographs of representative histological sections of the lung of: 
(A) Control group showing normal appearance (H&E × 100). 
(B) CP group showing foci of oedema and congestion, marked thickening of the alveolar septa and the alveolar lining is 
prominent (H&E × 200). 
(C) Higher power showing increased cellularity of the alveolar septa by inflammatory cells and extravasated blood (H&E × 400). 
(D) CP/Qur group showing thickening of the alveolar septa in 60% of all examined fields (H&E × 400). 
A B 
C 
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Lung of the combined group showed thickening of 
the alveolar septa in 60% of all examined fields. 
 
4. Discussion 
The adverse and serious side effects of potent 
chemotherapeutic agents constitute a major problem 
that limits their optimal use. CP is one of the most 
effective chemotherapeutic agents used in treatment of 
cancers of lung (Zhang et al., 2006), breast (Hirano et al., 
2008), ovary (Donato et al., 2004), prostate (Nicolini et 
al., 2004), leukemia, (Rao et al; 2005) and lymphomas.  
Cancer patients usually suffer from lung toxicity 
after CP therapy (Malik et al., 1996) that is characterized 
by  hypoxemia, non-cardiogenic pulmonary edema, low 
lung compliance and widespread capillary leakage.  
In the present study, the effect of quercetin (Qur) 
in the treatment of acute lung injury produced from CP 
was evaluated. 
Intraperitoneal injection of CP resulted in significant 
decrease in body weight, and a significant increase in 
lung weight index in rats compared to untreated control 
group. The inflammation and edema after CP treatment 
may be responsible for the increase in lung weight 
indices.  
Administration of  quercetin  with CP showed a 
significant decrease in lung weight index compared to 
CP  alone treated group, this finding is agreement with 
the study of Carvalho et al.,(2010),  in which  
pretreatment with quercetin significantly attenuated the 
severity of acute pancreatitis as evidenced by effective 
reductions in the pancreatic wet weight/body weight 
ratio, biochemical indices, proinflammatory cytokines  as 
TNF-α , IL-1b , and IL-6,  myeloperoxidase activity, 
malondialdehyde formation, and an increase in 
antiinflammatory cytokine IL-10. Quercetin treatment 
also markedly suppressed the histological changes such 
as pancreatic edema, inflammatory cell infiltration, 
acinar cell necrosis, and the expression of TNF- α. Taken 
together; these results indicate that quercetin acting as 
an antiinflammatory and antioxidant agent. 
In addition, intercellular adhesion molecule-1 (ICAM-
1) plays a pivotal role in inflammatory responses, 
quercetin is an inhibitor of agonist induced ICAM-1 
protein and mRNA expression. The down-regulation of 
this adhesion molecules lead to reduction of 
inflammation and edema Kobuchi et al., (1999). 
In the present study, the production of MDA, which 
is an index of lipid peroxidation was increased 
significantly in lung homogenate compared to control 
group after CP administration. This observation is in line 
with many reports that demonstrated apparent 
elevation in lung TBARS following administration of CP 
(Patel, 1987, Venkatesan and Chandrakasan., 1995, 
Stankiewicz  et al., 2002).Increased MDA level observed 
following CP administration in the current work could be 
indirectly attributed to the decreased level of GSH, also 
CP has been proved to induce significant alterations in 
the activity of NADH and NADPH2, likely to be 
responsible for the ultrastructural changes within 
mitochondria which include features of mitochondrial 
damage with disruption of mitochondrial membranes. 
We assume that an increase in MDA level in lung 
homogenates may be a biochemical evidence of these 
changes. 
Administration of quercetin with CP showed a 
significant decrease in  thelevelof TBARS compared to 
CP treated rats. This activity may be due to the ability of 
quercetin to inhibit lipid peroxidation by scavenging 
oxygen radicals (Jovanovic et al., 1994), terminating the 
chain-radical reaction, chelating metal ions (Afanas'ev et 
al., 1989) to form inert complexes that cannot take part 
in the conversion of superoxide radicals and hydrogen 
peroxide into hydroxyl radicals. 
 Also,Şekeroğlu et al., (2011) suggest that quercetin 
supplementation attenuates CP induced cardiotoxicity, 
urotoxicity and genotoxicity through a mechanism 
related to their ability to decrease oxidative stress and 
inflammation. 
Administration of CP in the current study reduced 
the lung content of GSH by about 83%. This could be due 
to the decreased expression of this antioxidant during 
bronchial cellular damage. CP metabolism produces 
highly reactive electrophiles that lead to electrophilic 
burden on the cells and also due to the formation of 
acrolein, which deplete GSH contents (McDiarmid et al., 
1991). 
 This is in line with other reports that demonstrated 
GSH reduction or depletion following CP challenging in 
animals. 
 Patel and Block (1985); Venkatesan and 
Chandrakasan (1995); Sulkowska et al. (2002); Manda 
and bhatia (2003) reported that, CP is capable of 
reducing the level of tissue GSH in both mice and rats. 
Administration quercetin with CP showed a significant 
increase  in  the level of GSH compared to the  negative 
control group, and  a  significant increase  in  the level of 
GSH compared to the  CP treated group. These findings 
are in agreement with the investigation conducted by 
Sekeroğlu et al. (2010) through which quercetin (50 
mg/kg/day) for 10 days alone or in combination with CP  
showed  significant decreases in the  level of GSH  
resulted from this quercetin supplementation attenuates 
CP induced cardiotoxicity, urotoxicity and genotoxicity 
through a mechanism related to their ability to decrease 
oxidative stress, inflammation,  its free radicals 
scavenging activity and its antioxidant activity. 
In this study, CP (150 mg/kg) increased the lung 
activity of SOD by about 95.5% compared to untreated 
control group.Such controversy could be explained in 
virtue of the postulate that the CP-induced increase in 
lung SOD activity is rather a compensatory event that 
occurred indirectly due to the oxidant injurious effect of 
CP and not due to a direct effect of the drug 
Administration of quercetin with CP showed a 
significant decrease in the level of lung SOD compared 
to the positive control group, this inhibition could 
presumably be explained as a consequence of less 
availability of the substrates for these enzymes 
(superoxide radical or free radicals) due to the reported 
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superoxide radical scavenging effect as SOD is the only 
known enzyme that uses free radicals as a substrate.  
In this study, CP (150 mg/kg) increased serum level 
of both total protein and LDH compared to negative 
control group.These events are indicative of airway 
and/or alveolar cell damage, airway cell influx, and 
microvascular leakage. In addition, this elevation could 
potentially be attributed to their release from the 
cytoplasm into the blood circulation after rupture of the 
plasma membrane and cellular damage due to 
generation of reactive oxygen species and other free 
radicals during CP exposure. 
Administration of quercetin with CP showed a 
significant decrease in serum level of both total protein 
and LDH compared to positive control group, this could 
be due to the ability of quercetin to reduce free radical-
induced oxidative damage in the lung. 
One of the essential mediators of inflammation in 
human body is the cytokines. TNF-α, one of the chief 
cytokines, is involved in provoking acute inflammatory 
responses in high dose CP administration. 
In the present study, CP administration showed 
significant increase in the serum level of TNF-α 
compared to negative control group. 
This result is in agreement with the investigation 
reported by Kumar et al. (2011) who showed there was a 
significant rise in the levels of TNF-α in the serum of CP 
intoxicated rats as compared to that of control   rats. 
In the present study, administration of quercetin 
with CP significantly decreased  TNF-α level compared to 
the CP-treated group.This result is in agreement with the  
investigation reported by Granado-Serrano et al. (2012) 
at which quercetin attenuated TNF-induced 
inflammation in hepatic cells by inhibiting the NF-κB 
Pathway, also quercetin  administration for 4 weeks 
resulted in decreased expression levels of mRNA for 
TNF-α and iNOS genes and decreased secretion of TNF-α 
protein and production of NO by lipopolysaccharides 
stimulated macrophages from both senescent and 
young mice (Qureshi et al., 2011). 
Histopathological examination of lung specimens 
isolated from CP-treated rats showed congestion, 
damage, and/or edema of interalveolar septa, 
neutrophilic and macrophages infiltration. Sulkowska 
and sulkowski (1998) demonstrated that congestion and 
edema may be due to the changes produced by CP in 
epithelial cell structure as well as alveolocapillary 
permeability. Treatment with quercetin showed that less 
lung damage, no areas of intralobular necrosis with less 
inflammatory infiltration in lung, thickening of the 
alveolar septa in 60% of examined field.  
In conclusion, the results indicate that quercetin 
partially protects healthy lung cells against 
cyclophosphamide injury.  
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